Published in Eur J Cancer on September 16, 2013
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol (2014) 1.04
Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. Front Cell Dev Biol (2016) 0.84
Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol (2015) 0.84
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. Oncotarget (2015) 0.82
Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC. Neoplasia (2015) 0.77
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. Oncotarget (2015) 0.76
Kidney cancer: Intermittent sunitinib is an effective renal carcinoma treatment. Nat Rev Urol (2017) 0.75
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. Int J Clin Oncol (2016) 0.75